Rajendrakumar Patel, Wilbert S. Aronow, Laxeshkumar Patel, Kaushang Gandhi, Harit Desai, Dhiraj Kaul, Sumir P. Sahgal
Med Sci Monit 2012; 18(4): RA31-39
Available online: 2012-04-01
Pulmonary arterial hypertension (PAH) is a chronic progressive disease of the pulmonary vasculature characterized by elevated pulmonary arterial pressure and secondary right ventricular failure. PAH is considered a life-threatening condition unless treated. This article provides a comprehensive review of controlled and uncontrolled trials to define the risk-benefit for different therapeutic options of this clinical disorder. Relevant published articles were identified through searches of the National Center for Biotechnology PubMed database. All therapeutic measures for PAH were discussed. Six drugs have been approved in the United States for the treatment of PAH. Extensive medical advancement has been achieved in treatment of PAH. However, none of the approved therapies have shown ability to cure the disease. New research should be performed to develop promising new therapies.
Keywords: Hypertension, Pulmonary - therapy, Drug Therapy, Combination, Antihypertensive Agents - therapeutic use